MX2024006168A - Composicion farmaceutica y uso de la misma. - Google Patents
Composicion farmaceutica y uso de la misma.Info
- Publication number
- MX2024006168A MX2024006168A MX2024006168A MX2024006168A MX2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A MX 2024006168 A MX2024006168 A MX 2024006168A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- mutation
- furmonertinib
- egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111404293.6A CN116159062A (zh) | 2021-11-24 | 2021-11-24 | 药物组合物及其用途 |
| PCT/CN2022/133171 WO2023093663A1 (en) | 2021-11-24 | 2022-11-21 | Pharmaceutical composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006168A true MX2024006168A (es) | 2024-06-11 |
Family
ID=86416859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006168A MX2024006168A (es) | 2021-11-24 | 2022-11-21 | Composicion farmaceutica y uso de la misma. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250017927A1 (OSRAM) |
| EP (1) | EP4436580A4 (OSRAM) |
| JP (1) | JP2024539476A (OSRAM) |
| KR (1) | KR20240124921A (OSRAM) |
| CN (2) | CN116159062A (OSRAM) |
| AU (1) | AU2022397653A1 (OSRAM) |
| CA (1) | CA3238480A1 (OSRAM) |
| IL (1) | IL312874A (OSRAM) |
| MX (1) | MX2024006168A (OSRAM) |
| WO (1) | WO2023093663A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
| CN116854694B (zh) * | 2023-07-04 | 2024-07-09 | 北京浦润奥生物科技有限责任公司 | [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| JP7752617B2 (ja) * | 2019-12-23 | 2025-10-10 | ブループリント メディシンズ コーポレイション | Ｅｇｆｒの変異型の阻害剤 |
| WO2023035223A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海艾力斯医药科技股份有限公司 | 药物组合物及其用途 |
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
-
2021
- 2021-11-24 CN CN202111404293.6A patent/CN116159062A/zh active Pending
-
2022
- 2022-11-21 EP EP22897746.8A patent/EP4436580A4/en active Pending
- 2022-11-21 KR KR1020247020083A patent/KR20240124921A/ko active Pending
- 2022-11-21 AU AU2022397653A patent/AU2022397653A1/en active Pending
- 2022-11-21 CN CN202280078292.3A patent/CN118678958A/zh active Pending
- 2022-11-21 JP JP2024530487A patent/JP2024539476A/ja active Pending
- 2022-11-21 CA CA3238480A patent/CA3238480A1/en active Pending
- 2022-11-21 MX MX2024006168A patent/MX2024006168A/es unknown
- 2022-11-21 IL IL312874A patent/IL312874A/en unknown
- 2022-11-21 US US18/712,357 patent/US20250017927A1/en active Pending
- 2022-11-21 WO PCT/CN2022/133171 patent/WO2023093663A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4436580A1 (en) | 2024-10-02 |
| AU2022397653A1 (en) | 2024-07-04 |
| CA3238480A1 (en) | 2023-06-01 |
| KR20240124921A (ko) | 2024-08-19 |
| US20250017927A1 (en) | 2025-01-16 |
| CN118678958A (zh) | 2024-09-20 |
| CN116159062A (zh) | 2023-05-26 |
| JP2024539476A (ja) | 2024-10-28 |
| IL312874A (en) | 2024-07-01 |
| WO2023093663A1 (en) | 2023-06-01 |
| EP4436580A4 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012131A (es) | Composicion farmaceutica, uso de la misma y metodo para tratar el cancer | |
| MX2022015695A (es) | Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma. | |
| WO2021243280A3 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| MX2022010128A (es) | Compuestos macrocíclicos y usos de estos. | |
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| Park et al. | The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib | |
| MX2024002822A (es) | Composicion farmaceutica y uso de la misma. | |
| MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
| CA2902144A1 (en) | Methods and compositions for treating cancers having acquired resistance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
| BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
| ZA202210640B (en) | Deuterated oxophenylarsine compound and use thereof | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| Negi et al. | Three weekly versus weekly cisplatin as radiosensitizer in head and neck cancer: a decision dilemma | |
| MX2025002967A (es) | Composicion farmaceutica y uso de la misma | |
| CA2514227A1 (en) | Combination therapy of zd6474 with 5-fu or/and cpt-11 | |
| WO2006110176A3 (en) | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor | |
| NO20044498L (no) | Kombinasjonsterapi for behandling av cancer | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
| Nobile et al. | A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients | |
| Giuliani et al. | Maintenance therapy in colon cancer | |
| MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
| TW200608959A (en) | Treatment with oxaliplatin and an egfr-inhibitor | |
| PH12021551951A1 (en) | Combination therapies for use in treating cancer |